Genome-wide association studies have identified thousands of genetic variants that are associated with disease 1 . Most of these variants have small effect sizes, but their downstream expression effects, so-called expression quantitative trait loci (eQTLs), are often large 2 and celltype-specific [3] [4] [5] . To identify these celltype-specific eQTLs using an unbiased approach, we used single-cell RNA sequencing to generate expression profiles of ~25,000 peripheral blood mononuclear cells from 45 donors. We identified previously reported cis-eQTLs, but also identified new celltype-specific cis-eQTLs. Finally, we generated personalized co-expression networks and identified genetic variants that significantly alter co-expression relationships (which we termed 'co-expression QTLs'). Singlecell eQTL analysis thus allows for the identification of genetic variants that impact regulatory networks.
Genome-wide association studies have identified thousands of genetic variants that are associated with disease 1 . Most of these variants have small effect sizes, but their downstream expression effects, so-called expression quantitative trait loci (eQTLs), are often large 2 and celltype-specific [3] [4] [5] . To identify these celltype-specific eQTLs using an unbiased approach, we used single-cell RNA sequencing to generate expression profiles of ~25,000 peripheral blood mononuclear cells from 45 donors. We identified previously reported cis-eQTLs, but also identified new celltype-specific cis-eQTLs. Finally, we generated personalized co-expression networks and identified genetic variants that significantly alter co-expression relationships (which we termed 'co-expression QTLs'). Singlecell eQTL analysis thus allows for the identification of genetic variants that impact regulatory networks.
Previously, purified cell types 4, [6] [7] [8] or deconvolution methods 9, 10 have been used to identify celltype-specific eQTLs. However, these methods are biased toward specific cell types or are of limited use for less-abundant cell types and dependent on accurately defined marker genes 11 . In contrast, single-cell RNA sequencing (scRNA-seq) can be used to investigate rare cell types 12 and thus enables identification of celltype-specific eQTLs using an unbiased approach. Indeed, proof of concept was previously shown in a study on 15 individuals, where 92 genes were studied in 1,440 cells 13 .
Here we studied celltype-specific effects of genetic variation on genome-wide gene expression by generating scRNA-seq data of ~25,000 peripheral blood mononuclear cells (PBMCs) from 45 donors of the population-based cohort study Lifelines Deep 14 . After quality control (Methods and Supplementary Fig. 1 ), we first assessed the extent to which previously reported cis-eQTLs from bulk whole blood, using either 94 DeepSAGE samples 15 (a 3′ -end-oriented RNA-sequencing strategy similar to our scRNAseq approach) or 2,116 RNA-seq 11 samples, also show significant effects in the scRNA-seq dataset. For this analysis, we treated the scRNA-seq data as representing bulk PBMCs (by averaging expression levels of all cells per gene per sample, referred to as 'bulk-like PBMCs'). We detected 50 and 311 significant cis-eQTLs (gene-level false-discovery rate (FDR) of 0.05) that were previously reported in the DeepSAGE 15 and RNA-seq 11 study, respectively ( Fig. 1a and Supplementary Table 1 ). Although only small proportions (8% and 1%, respectively) of previously reported cis-eQTLs were significant in our scRNA-seq analysis, 96% and 90.4% had identical allelic directions as in the DeepSAGE 15 and RNA-seq 11 studies, respectively, indicating that these cis-eQTLs reflect similar regulatory effects. The few discordant eQTLs may reflect the slightly different sample composition of both datasets (PBMCs versus whole blood) and the relatively few sequence reads targeting the 3′ -end of genes in the bulk RNA-seq dataset.
We subsequently performed a genome-wide cis-eQTL discovery analysis on the bulk-like PBMCs. Separate cis-eQTL analyses were conducted on each of the identified major cell types (cell type classification was performed using Seurat 16 ; Supplementary Fig. 2a,b) by averaging the normalized gene expression of all cells per cell type, gene, and donor. In total, 379 unique top cis-eQTLs were identified, reflecting 287 unique eQTL genes (gene-level FDR of 0.05; Table 1 ), as sometimes, in different cell types, different single-nucleotide polymorphisms (SNPs) showed the most significant association for an eQTL gene. While 331 (reflecting 249 unique cis-eQTL genes) of these 379 cis-eQTLs were significant in the bulk-like PBMC eQTL analysis, 48 cis-eQTLs (reflecting 38 unique cis-eQTL genes) were only detected in specific cell types (i.e., 'celltype-dependent' eQTLs; Supplementary Table 2) .
We subsequently attempted to replicate these eQTLs. For the 249 eQTL genes found in the bulk-like PBMC analysis, 233 ciseQTLs were testable and 181 (78%) were associated with the same SNP (90.1% shared allelic direction; Supplementary Table 2) in the wholeblood RNA-seq eQTL dataset 11 . For the 48 celltype-dependent cis-eQTLs, 29 (60%) were replicated in the RNA-seq dataset 11 . This lower percentage suggests that in bulk RNA-seq datasets, celltype-dependent eQTLs might become too diluted, resulting in low statistical power to recover these. While this most likely happens for rare cell types, we also observed this in common cell types. For instance, in the most abundant cell type (CD4 + T cells), rs2272245 significantly affects expression of the TSPAN13 gene in cis (P = 2.21 × 10 −6 ). However, this effect was not significant in the bulk-like PBMCs (P = 0.88), because TSPAN13 is lowly expressed in CD4 + T cells, whereas it is highly expressed in dendritic cells, where it did not show a cis-eQTL effect (Fig. 1b) . Cis-eQTLs might also be missed in bulk data, because they might show opposite allelic effects across different cell types. We could not study this in detail due to lack of power, given the sample size and limited number of cells for rare cell types ( Supplementary Fig. 2c ). Nevertheless, in CD4 + T cells, the A allele of rs4804315 significantly decreased expression of ZNF414 in cis (P = 6.09 × 10 ), whereas in natural killer cells this allele increased expression of ZNF414 at nominal significance (P = 0.0339; Fig. 1b) . However, the possibility that, specifically in natural killer cells, the effect of rs4804315 on ZNF414 expression is the result of a residual effect on ZNF414 expression of a second, independent variant cannot be excluded.
Since some cis-eQTLs did not replicate in the wholeblood bulk RNA-seq data, we subsequently investigated eQTL datasets of purified cell types. Indeed, 3 of 19 remaining celltype-dependent
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NATuRe GeNeTicS cis-eQTLs were detected (each with consistent allelic direction) in purified eQTL datasets of the Blueprint consortium (naive CD4 + T cells and CD14 + monocytes) 17 or Kasela et al. (CD4 + and CD8 + T cells) 6 (Supplementary Table 3 ). Hence, only 16 celltype-dependent cis-eQTLs were not identified before using bulk eQTL datasets of blood or purified immune cells. Although some cis-eQTLs were only significant in specific cell types, this does not prove celltypespecificity; power is lacking to detect many cis-eQTLs, particularly in less-abundant cell types. Ways to partially overcome this include using methods that consider multiple eQTL datasets together, such as eQTL-BMA 18 or Meta-Tissue
19
. However, these methods are currently computationally too demanding for large scRNA-seq data or do not define the cell type in which the eQTL effect occurs 19, 20 . A major advantage of using scRNA-seq data is its flexibility, which allows any cell population of interest to be selected for eQTL analysis. In contrast, when using RNA-seq data of purified cell types, one cannot retrieve data from cell subtypes. Moreover, while finer differences between cell subtypes may be detectable using gene 
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NATuRe GeNeTicS expression profiles, it is not always recapitulated by different cell membrane markers, complicating cell sorting. Here we show the added value of performing eQTL analysis on cell subtypes using two monocyte subsets: classical (cMonocytes) and nonclassical monocytes (ncMonocytes). When plotting Spearman's rank correlation of each top eQTL for cMonocytes against that for ncMonocytes, several examples were identified that pinpointed the eQTL effect specifically to cMonocytes (Fig. 1c) . Two such examples, which were previously identified in RNA-seq data of purified CD14 + monocytes 17 , are shown in Fig. 1d . The scRNA-seq data now allowed us to specifically assign these effects to cMonocytes (Fig. 1d ). Despite having lower power for detecting eQTLs in ncMonocytes due to an abundance almost five times lower compared to cMonocytes ( Supplementary Fig. 2b ), power in the ncMonocytes remains sufficiently high to detect several other significant ncMonocyte ciseQTLs (Fig. 1e and Supplementary Table 2 ).
Another opportunity of scRNA-seq data is to use it for determining whether genetic variants can alter gene co-expression. Although 
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recently genes and environmental factors altering the effect size of eQTLs ('context-specific eQTLs') have been identified in bulk RNAseq eQTL datasets 11, 21 , a large sample size was required to ensure sufficient power. In contrast, scRNA-seq data enables generation of co-expression networks on an individualdonor basis, which vastly reduces the number of samples required to identify SNPs altering co-expression relationships. This enabled us to study whether SNPs showing cis-eQTL effects also affect the co-expression relationship of the cis-eQTL genes with other genes, which we define as 'coexpression QTLs' . We confined our analysis to the most abundant cell type (CD4 + T cells) and calculated the co-expression between individual pairs of genes using Spearman's rank correlation. We restricted the analysis to the 145 cis-eQTL genes identified in CD4 + T cells (Table 1) , thereby increasing the likelihood of finding coexpressed genes that are modulated by the same genetic variant. Of these, 102 genes showed variance in gene expression within each of the 45 donors and were investigated. For two of these genes, we identified significant co-expression QTLs: 93 co-expression QTLs were detected for RPS26 and one for HLA-B (P ≤ 1.27 × 10 −7
, corresponding to an eQTL-gene level FDR of 0.05). The most significant interaction was found for rs7297175, affecting the co-expression between RPS26 and RPL21 (P = 2.70 × 10 ), we identified significant co-expression QTLs for three eQTL genes (Supplementary Table 4 ): 13 additional co-expression QTLs were found for RPS26 and one for SMDT1. Due to co-expression between genes, we cannot rule out that the 106 co-expression QTLs identified for RPS26 are actually representing just one effect.
To assess the robustness of the identified co-expression QTLs, we tested whether they remained significant after geneexpression imputation, which was used to overcome the problem that, in scRNA-seq data, many genes are often undetected despite being expressed (i.e., zero-inflated expression). Several computational strategies have been developed to do this [22] [23] [24] . However, most current methods are either computationally too demanding for large datasets like ours 23 or cannot sufficiently impute the 94.1% zerovalues present in our dataset 24 . To overcome this, we used MAGIC 22 , a method that imputes geneexpression levels for nearly every gene. To prevent imputation from removing effects of genetic differences between donors or cell types, we performed imputation for each donor separately and again only for CD4 + T cells (see "Data availability" in Methods). In general, imputation worked well, but in some circumstances artifacts were introduced ( Supplementary  Fig. 3 ). Therefore, we only used the imputed geneexpression data to determine whether the co-expression QTLs identified before imputation remained significant after imputation (Supplementary Table 4 ). Of the three eQTL genes that were involved in a co-expression QTL, two of three top co-expression QTLsrs7297175 (affecting the co-expression between RPS26 and RPL21, P = 3.97 × 10 −12
; Fig. 2c ) and rs4147641 (affecting the co-expression between SMDT1 and RPS3A, P = 2.57 × 10 −4 )-remained after imputation (Supplementary Table 4 ). Subsequently, we were able to replicate both effects in a wholeblood bulk RNA-seq eQTL dataset 11 (P = 1.69 × 10 −3 for RPS26-RPL21 (Fig. 2d) , P = 1.59 × 10 −4 for SMDT1-RPS3A; Supplementary Table 4) . Notably, SNP rs7297175, affecting the co-expression between RPS26 and 106 other genes, is in near-perfect linkage disequilibrium with the type I diabetes SNP rs11171739 25 (r 2 = 0.98). Therefore, the numerous co-expression QTLs for RPS26 may shed new light on RPS26 and its link with type I diabetes. This interaction effect was also observed in other cell types ( Supplementary Fig. 4 ), indicating that it is not celltypespecific. In addition, various analyses were performed to rule out potential technical confounders (Methods).
The co-expression QTL analysis as outlined above highlights another advantage of scRNA-seq data; with PBMCs from only 45 donors, we could identify effects that would otherwise only become apparent in large-scale (2,116 samples) bulk RNA-seq eQTL datasets 11 . Due to Simpson's paradox 26 , it may occur that when looking at all individuals together, the interaction between two genes does not show a correlation, while each of the individuals separately do show a correlation. Therefore, even though the effect may be observed in bulk RNA-seq data, the true correlation will only be identified using scRNA-seq data.
The eQTL and co-expression QTL analyses performed in this study show the benefit of scRNA-seq data for linking genetic variation to geneexpression regulation. In addition to these analyses, we expect scRNA-seq data to offer many other opportunities for selecting cells of interest for eQTL and co-expression QTL analysis. For example, one could use the intercellular variation within scRNAseq data to group cells along the cell cycle 13 , along a differentiation path 27 , or along a response to an environmental stimulus 28 . By doing so, one might identify eQTLs or co-expression QTLs that are influenced by cell cycle phase, differentiation, or environmental status.
In conclusion, this proof-of-concept study shows the feasibility of using scRNA-seq data for eQTL and gene-gene interaction analysis. The identified eQTLs and co-expression QTLs matched well with previously reported wholeblood RNA-seq data. Moreover, we extended the list of genes known to be under genetic control or specified the cell type in which the effect is most prominent. Finally, several SNPs were linked to modulation of gene co-expression, implying that gene regulatory networks can be highly personal. We expect that larger single-cell eQTL datasets will enable the identification of many celltype-specific eQTLs and genetic variants that affect regulatory network relationships.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0089-9. Total (unique) 287
The median number of cells per donor correlates fairly well with the number of detected cis-eQTL genes. In total, 379 unique top cis-eQTL effects, reflecting 287 unique eQTL genes, have been identified in the total dataset. Within each cell type, the number of unique cis-eQTL genes that we identified was equal to the number of unique, top cis-eQTL effects.
Ethics approval and consent to participate. The LifeLines DEEP study was approved by the ethics committee of the University Medical Center Groningen, document number METC UMCG LLDEEP: M12.113965. All participants signed an informed consent form before study enrollment. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Isolation and preparation of PBMCs. Whole blood of 47 donors from the generalpopulation Lifelines Deep (LLD) cohort 14 was drawn into EDTA-vacutainers (BD). Within 2 h, peripheral blood mononuclear cells (PBMCs) were isolated using Cell Preparation Tubes with sodium heparin (BD). For all procedures, PBMCs were kept in RPMI1640 supplemented with 50 µ g/mL gentamicin, 2 mM l-glutamine, and 1 mM pyruvate. Isolated PBMCs were cryopreserved in RPMI1640 containing 40% FCS and 10% DMSO. Within one month, PBMCs were further processed for scRNA-seq. First, cells were thawed in a 37 °C water bath until almost completely thawed, after which the cells were slowly washed in warm medium. After washing, cells were resuspended in medium and incubated for 1 h in a 5° slant rack at 37 °C in a 5% CO 2 incubator. After this 1 h resting period, cells were washed twice in medium supplemented with 0.04% bovine serum albumin. Cells were counted using a hemocytometer and cell viability was assessed by Trypan Blue. Eight sexbalanced sample pools were prepared, each containing 1,750 cells/donor from six (or five) donors (10,500 cells).
Single-cell library preparation and sequencing. Single cells were captured using the 10x Chromium controller (10x Genomics) according to the manufacturer's instructions (document CG00026) and as previously described 29 . Each sample pool was loaded into a different lane of a 10x chip (Single Cell A Chip Kit, 120236). cDNA libraries were generated using the Single Cell 3′ Library & Gel Bead kit version 2 (120237) and i7 Multiplex kit (120262), in line with the company's guidelines. These libraries were sequenced using a custom program (27-9-0-138) on eight lanes of an Illumina HiSeq4000 using a 75-bp paired-end kit, per GenomeScan (Leiden, The Netherlands) sequencing guidelines. In total, 28,855 cells were captured and sequenced to an average depth of 74 kb.
Alignment and initial processing of sequencing data. CellRanger v1.3 software with default settings was used to demultiplex the sequencing data, generate FASTQ files, align the sequencing reads to the hg19 reference genome, filter cell and UMI (unique molecular identifier) barcodes, and count gene expression per cell (see "Data availability" section, below).
Demuxlet algorithm: demultiplexing samples per lane and doublet detection.
Genotypes of the LLD samples were previously generated 14 and were phased using Eagle v2.3 30 and imputed with the HRC reference panel 31 using the Michigan Imputation Server 32 . As genotype data for each donor (except two) was available, we used the Demuxlet method 33 , which uses variable SNPs between the pooled individuals to determine which cell belongs to which individual and to identify doublets (two cells encapsulated in a single droplet by the 10x Chromium controller).
To determine how well every genotype matches each cell, a likelihood score was calculated by the formula Here, c is the cell, s is the individual, v denotes the unique genetic variants (SNPs) found on the reads of the cell, and d cv the number of unique reads overlapping with the vth variant from the cth cell. b cvi is the variant-overlapping base call from the ith read, representing reference (R), alternate (A), and other (O) alleles respectively. e cvi is a latent variable indicating whether the base call is correct (0) or not (1), and g is the true genotype. This likelihood score was calculated by taking into account the genotype probabilities of a sample at all known SNPs, the variant-overlapping base calls with base quality (Phred quality score) > 15, and a probability that the base was not called correctly, which is fixed at 0.001. In this way, for each pool of cells, the genotype within this pool with the highest likelihood was assigned as the most likely person the cell belonged to.
To identify doublets, likelihoods for a 50/50 ratio of all possible combinations of two genotypes were calculated, similarly to the way singlets were calculated but now considering two genotypes at the same time. To consider a mix of genotypes from two individuals, the following formula was used: Here, s 1 and s 2 are the two individuals, g 1 and g 2 the corresponding true genotypes and α is the expected proportion of the SNPs in every cell for each of the individuals. An α of 0.5 was consistently used, assuming a 50/50 ratio. The maximum likelihood in the mixed-genotype case was divided by the maximum likelihood in the singlet case to obtain a likelihood ratio. If this ratio was less than 1/t for some number t, the cell was considered a singlet of the sample corresponding to the maximum singlet likelihood. If the ratio was greater than t, the cell was considered a doublet. When the ratio was in between 1/t and t, the cell was called inconclusive: no confident call could be made from which sample(s) the cell originated. The decision boundary factor t was fixed at 2. In theory, if there are n samples in a lane, (n -1)/n doublets can be identified using the Demuxlet algorithm, because doublets from the same individual (1/n) cannot be identified. Further details of the algorithm can be found in Kang et al. 33 Using the Demuxlet algorithm, we could confidently assign the majority (99.8%) of cells to one of the individual donors (singlets) or to two different donors (doublets) ( Supplementary Fig. 1a and Supplementary Table 5 ). Remarkably, in two of eight sample pools, no cells were assigned to one of the six donors within the pool. Moreover, the detected doublet rate in those sample pools was abnormally high (17.5% and 21.1%, while 3-4% was expected; Supplementary Table 5 ). This is most probably due to a sample mix-up in the lab that resulted in an artificially high doublet rate. Since the genotypes of these two mixed-up samples were not available, those samples were excluded from the analysis (marked as 'doublet').
Two additional tests were performed to confirm the correct assignment of cells using Demuxlet. First, we determined what would happen if the cells did not match with their genotypes by taking six random genotypes not present in the sample pool itself. This resulted in 0.02% of the cells assigned as singlets, 0.03% inconclusive and 99.95% assigned as doublets. Second, the number of reads mapping to the Y-chromosome was determined for the singlets of each donor. Cells belonging to a female donor showed (almost) no Y-reads (mismapping reads 34 may explain the few sporadic Y-reads), whereas the majority of cells from male donors did ( Supplementary Fig. 1b) . So, the correct gender for each of the donors could be confirmed by looking at the number of Y-reads. These tests indicated that the Demuxlet method was correctly assigning cells to their respective donor and suitable for detecting sample swaps.
Cell type classification. Version 1.4 of the R package Seurat
16 was used to determine the cell types using the raw UMI counts from CellRanger. First, all genes that were not detected in ≥ 3 cells were removed. Cells in which > 5% of the UMIs mapped to the mitochondrially encoded genes were discarded, as this can be a marker of poor-quality cells; broken cells will leak cytoplasmic RNA, while the mitochondrial RNA content is retained inside the mitochondria 35 . Also, cells expressing > 3,500 genes were considered outliers and discarded ( Supplementary  Fig. 1c and Supplementary Table 6 ). Finally, all cells that were marked as doublets or inconclusive by the Demuxlet method were discarded. Supplementary Fig. 1d shows a t-distributed stochastic neighbor embedding (t-SNE) plot 36 in which all cells failing the above QCs are visualized. Library-size normalization was performed on the UMI-collapsed gene expression for each barcode by scaling the total number of transcripts per cell to 10,000. The data was then log2 transformed. In total, 25,291 cells and 19,723 genes (an average of 1,147 detected genes/cell; see "Data availability" section below) were used in the cell type determination.
Linear regression was used to regress out the total number of UMIs and the fraction of mitochondrial transcript content per cell. The variable genes were identified using Seurat's MeanVarPlot function, which sorts all genes into 20 bins based on their average expression (the mean of nonzero values) and calculates the dispersion (s.d. of all values) within each bin. Standard parameters were used, except that the bottom geneexpression cut-off (x.low.cutoff) and the bottom dispersion cut-off (y.cutoff) were each set to 1.0, resulting in the identification of 1,090 genes. These 1,090 variable genes were used in the principal component analysis (PCA). The first 16 principal components were used for cell clustering using Seurat's FindCluster function (default parameters, resolution 1.2) and a t-SNE plot was used to visualize this. Based on known marker genes and differentially expressed genes per cluster (found using Seurat's FindMarkers function), we could assign 11 cell types to the clusters, including some smaller cell subtypes ( Supplementary Fig. 2a,b and Supplementary Table 7 ). The smallest cluster we could detect consisted of plasma cells, making up 0.3% of the total PBMC population. eQTL analysis. To find the association between genotype and expression per cell type, genome-wide cis-eQTL analysis for 18,264 genes (only autosomal genes, gene expressed in at least 3 cells within the total dataset and in at least 1 cell within the cell type queried, within 100 kb distance of the SNP and the gene midpoint, MAF > 0.1, call rate > 0.95, Hardy-Weinberg equilibrium P > 0.001) was performed using our previously described eQTL pipeline, version 1.2.4 F (Supplementary Table 2 and see "Data availability") 11 . To assure sufficient power, cell types were merged to a more general classification: CD4 + ncMonocyte), B cells and DCs (CD1C + myeloid, mDC, and plasmacytoid, pDC). The mean expression per gene per cell type per donor was calculated on the normalized (z-score transformed) expression and used as input for the eQTL analysis. eQTLs were mapped using Spearman's rank correlation coefficient on imputed genotype dosages. eQTLs were considered significant at Letters NATuRe GeNeTicS a gene-level FDR of 0.05. To control the FDR at 0.05 we used the permutation method described in our previous study 2 . Here we permute the link between the genotypes and expression data and create an overall null distribution using all genes. We performed, in total, 10 permutations and for each gene use the total null distribution of all genes to determine a gene-level FDR; during FDR estimation only the most significant SNP per gene is used, both for the real analysis and for each of the permutations.
Concordance and detection.
Concordance with previously characterized, independent top eQTLs from a wholeblood DeepSAGE (3′ -end transcriptomics) 15 and RNA-seq study 11 were computed. For this, the mean expression per gene per individual of all cells was calculated, and the cis-eQTL mapping was confined to the independent top eQTLs found in the DeepSAGE 15 or RNA-seq 11 studies. Subsequently, detection of the same SNP-gene combination and concordance (with same allelic direction) were assessed between the significant top effects (Supplementary Table 1 ). We also determined how many of the 379 top eQTLs in our scRNA-seq dataset could be detected and with which allelic direction within the wholeblood RNA-seq study 11 . Similarly, we assessed detection rates and concordances with two studies containing RNA-seq data of purified cell types: Kasela et al. performed eQTL analysis on purified CD4
+ and CD8 + T cells 6 , whereas the data from the Blueprint consortium contains purified CD14 + monocytes and naive CD4 + T cells 17 (Supplementary Tables 2 and 3 ). Moreover, for the eQTLs that were specifically detected in cMonocytes and not ncMonocytes (Fig. 2d) , detection rates and concordances were determined using the RNA-seq data of the purified CD14
+ monocytes from the Blueprint consortium 17 .
Single-cell gene expression imputation. To overcome the zero-inflated expression, the computational method MAGIC 22 was used to impute practically all values of genes with at least some expression. MAGIC imputation (using the following parameters: 20 PCs, t = 4, k = 9, ka = 3, ε = 1) was performed separately per donor and only in the CD4 + T cells (see "Data availability"). The effect of MAGIC imputation was validated by comparing the co-expression of typical celltypespecific marker genes ( Supplementary Fig. 3 ).
Co-expression QTL analysis. For every individual, a Spearman's rank correlation coefficient was calculated between the expression of the cis-eQTL gene and all other genes. Given the large zero-inflation of scRNA-seq data, we only tested those 7,975 genes that showed variance in expression for each of the 45 samples. As a consequence, we could study 102 eQTL genes, of the 145 unique genes that showed a significant cis-eQTL effect in CD4 + T cells. For each of these combinations, a weighted linear model was used (co-expression ~ genotype, where weight is cellCount ), in which the explained variable is a Spearman correlation coefficient that describes the co-expression between the two genes, the genotype is the predictor, and the weights are the square root of the number of CD4 + T cells within the given sample ( Supplementary Fig. 5 ).
To determine the number of cis-eQTL genes for which we had identified a significant co-expression QTL, we performed 100 permutations (see "Data availability"). For the real analysis, we denoted the most significant co-expression QTL P value for each of the tested 102 eQTL genes (Supplementary Table 4) . For each permutation, we shuffled the genotype identifiers and re-ran the above analysis, including determination of the most significant co-expression QTL P value for each of the 102 eQTL genes (see "Data availability"). This subsequently enabled us to calculate an eQTL gene-level FDR 2 (using exactly the same multipletesting correction procedures as we employed for the detection of cis-eQTLs; see "eQTL analysis" section). An eQTL gene-level FDR of 0.05 was considered significant, i.e., the P value threshold of the most significant co-expression QTL P values at which 5% of the co-expression QTLs are significant in the permuted compared to the real data.
All significant co-expression QTLs were discovered using nonimputed gene expression data. We then assessed whether these co-expression QTLs were also significant when using the MAGIC-imputed gene expression data. Subsequently, we tested whether these co-expression QTLs replicated using a large wholeblood bulk RNA-seq dataset 11 (Supplementary Table 4 ). Finally, we attempted to falsify the observed co-expression QTL for rs7297175 on the co-expression between RPS26 and RPL21 by checking the following potential confounders:
• Potential sequence homology: no evidence was found for sequence homology between RPS26 and RPL21.
• Genotype-dependent mapping problems of RNA sequence reads: no evidence was found that the RPS26 cis-eQTL SNP rs7297175 has any SNP proxies (r 2 > 0.8) that are coding and that map within RPS26. As such, this suggests that potential genotype-dependent mapping biases of sequence-reads are unlikely.
• Multimapping of RNA sequence reads: no differences were found between individuals with regards to the number of sequence reads that were discarded due to multimapping of sequence reads to RPS26.
• Unexpected trans-eQTL on RPL21: no evidence was found that the RPS26 ciseQTL SNP rs7297175 is affecting the expression of RPL21 in trans.
• Genotype-dependent cell-subtype composition effects: the RPS26-RPL21 co-expression QTL is unlikely to be the result of a cell-subtype within the CD4 + T cell population, as this co-expression QTL effect is also significant within CD8 + T cells, within monocytes, and within NK cells ( Supplementary Fig. 4 ).
Accession codes. EGA: Processed (de-anonymized) single-cell RNA-seq data, EGAS00001002560.
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. Raw gene expression counts, MAGIC imputed CD4 + T cell gene expression, and eQTL and co-expression QTL summary statistics can be found under "Supplementary Data" at the website accompanying this paper (https:// molgenis58.target.rug.nl/scrna-seq/).
Processed (de-anonymized) single-cell RNA-seq data, including a text file that links each cell barcode to its respective donor, has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001002560. Gene expression and genotype data can be obtained and requested by filling in a single and short web form at https:// molgenis58.target.rug.nl/scrna-seq/. This form is subsequently reviewed by a single Data Access Committee, who will be able to approve access to both the raw gene expression and genotype data within 5 working days (during the holiday season there might be a slight delay). Once the proposed research is approved, access to the relevant gene expression or genotyped data will be free of charge. Access to the genotype and gene expression data is facilitated via the Lifelines workspace and the EGA, respectively. Sample metadata (age, gender, processing batch) is presented in Supplementary Table 8 .
Code availability. The original R code for Seurat 16 (https://github.com/satijalab/ seurat), Demuxlet 33 (https://github.com/statgen/demuxlet), MAGIC 22 (https:// github.com/KrishnaswamyLab/magic) and our in-house eQTL pipeline 2 (https:// github.com/molgenis/systemsgenetics/tree/master/eqtl-mapping-pipeline) can be found at GitHub. All custom-written code is made available via GitHub (https:// github.com/molgenis/scRNA-seq).
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Experimental design 1. Sample size
Describe how sample size was determined.
In this proof of concept study 47 donors were included. Previous eQTL studies have shown that this size is sufficient to detect eQTLs.
Data exclusions
Describe any data exclusions. Two donors were included from downstream analysis as no genotype information was available to confidently assign the cells to these donors.
Replication
Describe whether the experimental findings were reliably reproduced.
77.7% (181/233) of the tested top cis-eQTLs (16/249 could not be tested as gene expression data was not available in the whole blood RNA-seq data) found in the total PBMCs were replicated (with 90.1% concordance) in whole blood RNA-seq data. The top co-expression QTLs found in CD4+ T cells remained after imputation and were replicated in whole blood RNA-seq data.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
The 47 donors were semi-randomly assigned to any of the 8 sample pools, taking into account that no relatives and approximately an equal number of male and females were included in each sample pool.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
All data was anonimyzed during data collection. During analysis, genotype information was used to assign each cell to its donor.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
